{"product_id":"bayer-business-model-canvas","title":"Bayer Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer Business Model Canvas: Strategic Blueprint for Growth, R\u0026amp;D \u0026amp; Diversified Value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Bayer's business model—this concise Business Model Canvas reveals how Bayer creates value, scales across healthcare and agriculture, and sustains competitive advantage through partnerships, R\u0026amp;D, and diversified revenue streams; ideal for investors, consultants, and entrepreneurs seeking actionable, ready-to-use insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic R\u0026amp;D Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer runs strategic R\u0026amp;D collaborations with universities and biotech firms to share drug-discovery and agri-tech risks, co-funding projects that cut upfront costs—Bayer reported ~€1.8bn in external R\u0026amp;D investments and partnerships in 2024. By late 2025 Bayer pivoted more capital toward cell and gene therapy and next-gen biologicals, citing a 35% increase in alliance deal volume year-over-year and several co-funded trials entering Phase II.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Supply Chain Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer depends on a global network of 1,200+ logistics and wholesale partners to distribute medicines and crop inputs across 90+ countries; in 2024 this network moved products generating €44.1bn in pharma and crop science revenues, ensuring delivery to pharmacies and 25m+ farm customers. Strengthening these ties is crucial to sustain market share in emerging economies and remote regions where last-mile costs can add 8–15% to distribution spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Farming and AgTech Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with tech providers and data analytics firms power Bayer’s Climate FieldView and precision farming, integrating satellite imagery, soil sensors, and AI to deliver field-level insights; by 2024 FieldView covered ~95 million hectares globally and helped users increase yields by up to 6% in pilot studies. These alliances cut inputs and emissions—partner data show up to 12% fertilizer reduction—so farmers boost productivity while lowering environmental footprints.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Providers and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer partners with hospitals, insurers and national health services to secure reimbursement and patient access for specialty medicines, using real-world evidence to demonstrate value; in 2024 Bayer Pharmaceuticals reported core EPS contributing to a €49.0bn Group sales run-rate, strengthening payer negotiations.\u003c\/p\u003e\n\u003cp\u003eIn 2025 these ties shift toward value-based care and integrated pathways, with pilots linking outcomes to payments—Bayer cites outcome-based contracts in oncology and rare disease pilots covering ~5–10% of eligible patient cohorts in EU markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: reimbursement and access for specialty meds\u003c\/li\u003e\n\u003cli\u003e2024 Group sales context: €49.0bn (Bayer, FY 2024)\u003c\/li\u003e\n\u003cli\u003e2025 emphasis: value-based contracts, integrated care pathways\u003c\/li\u003e\n\u003cli\u003ePilot scale: ~5–10% eligible patients in EU outcome pilots\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Ventures for Sustainability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBayer forms joint ventures with environmental NGOs and carbon-credit platforms to hit its 2030 sustainability goals, targeting a 30% reduction in Scope 1+2 emissions and scaling regenerative agriculture across 5 million hectares by 2030, creating paid carbon services for farmers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJoint ventures: NGOs + marketplaces\u003c\/li\u003e\n\u003cli\u003eTargets: 30% Scope 1+2 cut by 2030\u003c\/li\u003e\n\u003cli\u003eScale: 5M hectares regenerative ag by 2030\u003c\/li\u003e\n\u003cli\u003eRevenue shift: product to paid services\/carbon credits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer scales services, data \u0026amp; sustainability—€1.8bn R\u0026amp;D, 95M ha FieldView, 2030 targets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer leverages 1,200+ distribution partners, ~€1.8bn external R\u0026amp;D spend (2024), FieldView on ~95M ha, and joint ventures targeting 30% Scope 1+2 cut and 5M ha regenerative ag by 2030, shifting revenue toward services and value-based care pilots covering ~5–10% eligible EU patients.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution partners\u003c\/td\u003e\n\u003ctd\u003e1,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExternal R\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e€1.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFieldView coverage\u003c\/td\u003e\n\u003ctd\u003e95M ha\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 Pharma\/Crop sales\u003c\/td\u003e\n\u003ctd\u003e€44.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup sales (2024)\u003c\/td\u003e\n\u003ctd\u003e€49.0bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue‑based pilot scale (2025)\u003c\/td\u003e\n\u003ctd\u003e5–10% eligible patients EU\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2030 targets\u003c\/td\u003e\n\u003ctd\u003e30% Scope1+2 cut; 5M ha regen ag\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Bayer detailing nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—aligned with real-world operations, competitive advantages, SWOT-linked insights, and polished for presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Bayer’s business model with editable cells, condensing R\u0026amp;D, product portfolios, and regulatory pathways into a one-page snapshot that saves hours of structuring and is ready for team collaboration or boardroom review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContinuous R\u0026amp;D investment funds discovery of new molecular entities in pharmaceuticals and novel crop traits, drives complex clinical trials and regulatory filings, and supports long-term lab work; Bayer spent €5.3bn on R\u0026amp;D in 2024 and reported ~35 active Phase I–III programs. By end-2025 AI-driven drug discovery reduced early lead times by roughly 30%, accelerating candidate ID and lowering preclinical costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBayer runs 120+ high-tech production sites worldwide to make chemical compounds, biologicals, and consumer health products, enforcing Good Manufacturing Practices (GMP) and strict environmental rules; in 2024 manufacturing accounted for ~48% of Bayer’s €44.1bn revenue, supporting supply consistency and quality across Crop Science, Pharmaceuticals, and Consumer Health.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarketing and Sales Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer deploys a specialized sales force of ~25,000 reps (2024 figure) to train healthcare professionals and give technical support to large-scale agricultural producers, driving €4.3bn in Crop Science services-related revenue in 2024. Marketing is locally adapted to regulations and cultures across 90+ markets, and by 2025 digital marketing plus e-commerce account for ~28% of Consumer Health sales, up from 18% in 2020.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Patent Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory compliance and patent management keep Bayer's IP and market access intact: Bayer filed ~2,200 patents worldwide in 2024 and spent €3.1bn on regulatory and safety affairs in 2023 to meet FDA and EFSA standards, protecting product lifecycles and revenue streams.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~2,200 patents filed (2024)\u003c\/li\u003e\n\u003cli\u003e€3.1bn regulatory spend (2023)\u003c\/li\u003e\n\u003cli\u003eMaintains FDA\/EFSA approvals for global markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Transformation and Data Analytics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIntegrating digital tools across Bayer—from precision breeding to patient monitoring—drives efficiencies and new products; by late 2025 Bayer reports using data analytics to cut supply‑chain lead times by ~12% and to improve demand-forecast accuracy by ~15% (internal pilots across Crop Science and Pharmaceuticals).\u003c\/p\u003e\n\u003cp\u003eManaging petabytes of agronomic, clinical, and IoT data funds platform products and services that aim to add €500m+ ARR by 2026 while lowering unit costs through predictive maintenance and SKU-level forecasting.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData-driven supply chain: ~12% lead-time cut\u003c\/li\u003e\n\u003cli\u003eForecast accuracy: ~15% improvement\u003c\/li\u003e\n\u003cli\u003eTarget digital ARR: €500m+ by 2026\u003c\/li\u003e\n\u003cli\u003eScope: petabytes from field sensors, trials, patient devices\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer ramps R\u0026amp;D €5.3B, 35 drug programs, 120+ sites and €500M+ digital ARR target\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBayer invests €5.3bn in R\u0026amp;D (2024) with ~35 active Phase I–III programs, runs 120+ GMP sites, employs ~25,000 sales reps, filed ~2,200 patents (2024), spent €3.1bn on regulatory (2023), and aims €500m+ digital ARR by 2026 while cutting supply lead times ~12% and forecast error ~15% by late 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e€5.3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive clinical programs\u003c\/td\u003e\n\u003ctd\u003e~35\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing sites\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales reps (2024)\u003c\/td\u003e\n\u003ctd\u003e~25,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents filed (2024)\u003c\/td\u003e\n\u003ctd\u003e~2,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory spend (2023)\u003c\/td\u003e\n\u003ctd\u003e€3.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital ARR target (2026)\u003c\/td\u003e\n\u003ctd\u003e€500m+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply lead-time cut\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForecast accuracy gain\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Bayer Business Model Canvas shown here is the actual deliverable, not a sample or mockup; it’s a direct snapshot of the exact file you’ll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order you’ll get this same professional, fully editable document—structured and formatted exactly as previewed, ready for presentation or customization.\u003c\/p\u003e\n\u003cp\u003eNo placeholders, no surprises—what you see is the file you’ll own and download instantly in its complete form.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749037060473,"sku":"bayer-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/bayer-business-model-canvas.png?v=1772212556","url":"https:\/\/growthsharematrix.com\/products\/bayer-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}